Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
216 results found
Apr 14, 2021
Publication
Novavax included/third party
Cell Host and Microbe
COVID-19
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Shen, Xiaoying, Tang, Haili, McDanal, Charlene, et al.
Apr 13, 2021
Publication
Collaborative
Annals of Internal Medicine
COVID-19, Matrix-M® adjuvant
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Follmann D, Fintzi J, Fay MP, et al.
Apr 7, 2021
Publication
Collaborative
New England Journal of Medicine
COVID-19, Matrix-M® adjuvant
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Shen X, Tang H, Pajon R, et al
Jan 25, 2021
Clinical trial protocol
COVID-19
Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa
Jan 14, 2021
Publication
Novavax led
Nature Communications
COVID-19
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Tian, Jing-Hui, Patel, Nita , Haupt, Robert , et al.
Jan 11, 2021
Publication
Novavax included/third party
Frontiers in Immunology
Malaria, Matrix-M® adjuvant
A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
Sing, Susheel K., Plieskatt, ordan, Chourasia, Bishwanath K., et al.
Dec 15, 2020
Publication
Novavax led
Molecular Pharmaceutics
RSV
Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution

Neutron and X-ray scanning reveal structure of a candidate vaccine's nanoparticles in a more realistic environment.

Krueger, Susan, Curtis, Joseph E. , Scott, Daniel R. , et al.
Dec 10, 2020
Publication
Novavax led
The New England Journal of Medicine
COVID-19
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, Cheryl, Albert, Gary, Cho, Iksung, et al.
Nov 25, 2020
Publication
Novavax led
Vaccine
COVID-19, Matrix-M® adjuvant
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Guebre-Xabier M, Patel N, Tian JH, et al.
Nov 4, 2020
Publication
Novavax led
Clinical Infectious Diseases
Seasonal influenza, Matrix-M® adjuvant
Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
Shinde, Vivek, Cai, Rongman, Plested, Joyce S., et al.